目的 探討復(fù)方血栓通膠囊聯(lián)合地爾硫䓬片治療氣陰兩虛型微血管性心絞痛的臨床療效。方法 選取2022年6月—2023年12月在河南中醫(yī)藥大學(xué)第三附屬醫(yī)院治療的氣陰兩虛型微血管性心絞痛患者81例，根據(jù)不同治療方案分成對照組（40例）和治療組（41例）。對照組患者口服鹽酸地爾硫䓬片，30 mg/次，3次/d。治療組在對照組基礎(chǔ)上口服復(fù)方血栓通膠囊，3粒/次，3次/d。兩組患者均進(jìn)行6周的治療。觀察兩組患者臨床療效，比較治療前后兩組患者中醫(yī)證候評分和Duke評分，全血高切黏度、全血低切黏度和血漿黏度，左心室射血分?jǐn)?shù)（LVEF）、6 min步行距離（6MWT）、內(nèi)皮素-1(ET-1)、超敏C反應(yīng)蛋白（hs-CRP）和低密度膽固醇（LDL-C）水平。結(jié)果 治療后，對照組和治療組總有效率分別為75.00%和95.12%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。經(jīng)治療，兩組中醫(yī)證候評分降低，而Duke評分升高（P<0.05），且治療后治療組中醫(yī)證候評分低于對照組，Duke評分高于對照組（P<0.05）。經(jīng)治療，兩組患者LVEF和6MWT水平比治療前明顯升高（P<0.05），且治療組較對照組升高更明顯（P<0.05）。經(jīng)治療，兩組患者全血高切黏度、全血低切黏度和血漿黏度均較治療前明顯降低（P<0.05），且治療組在各指標(biāo)較對照組降低更為顯著（P<0.05）。經(jīng)治療，兩組患者血清ET-1、hs-CRP和LDLC水平均較治療前明顯降低（P<0.05），且治療組各指標(biāo)較對照組下降更顯著（P<0.05）。結(jié)論 復(fù)方血栓通膠囊聯(lián)合地爾硫䓬片治療氣陰兩虛型微血管性心絞痛療效顯著，不僅能夠顯著改善患者心絞痛癥狀、疾病嚴(yán)重程度和血液流變學(xué)指標(biāo)，同時還能夠提升患者心功能狀態(tài)。

Objective Exploring the efficacy of Compound Xueshuantong Capsules combined with diltiazem in treatment of microvascular angina pectoris with Qiyin deficiency type. Methods Patients（81 cases） with microvascular angina pectoris with Qiyin deficiency type in the Third Affiliated Hospital of Henan University of Traditional Chinese Medicine from June 2022 to December2023 were divided into control（40 cases） and treatment（41 cases） group based on different treatments. Patients in the control group were po administered with Diltiazem Hydrochloride Tablets, 30 mg/time, three times daily. Patients in the treatment group were po administered with Compound Xueshuantong Capsules, 3 grains/time, three times daily. Patients in two groups were treated for 6 weeks.After treatment, the clinical evaluations were evaluated, the traditional Chinese medicine syndrome score and Duke score, whole blood high shear viscosity, whole blood low shear viscosity and plasma viscosity, the levels of LVEF, 6MWT, ET-1, hs-CRP and LDL-C in two groups before and after treatment were compared. Results After treatment, the total clinical effective rates in the control group and the treatment group were 75.00% and 95.12%, respectively, and the difference between the two groups was statistically significant（P＜0.05）. After treatment, TCM syndrome score decreased in both groups, but Duke score increased（P＜0.05）. After treatment, TCM syndrome score in the treatment group was lower than that in control group, Duke score was higher than that in control group（P＜0.05）. After treatment, LVEF and 6MWT levels in two groups were significantly higher than before treatment（P＜0.05）, and the increase in the treatment group was more significant than that in the control group（P＜0.05）. After treatment, the whole blood highshear viscosity, whole blood low-shear viscosity and plasma viscosity were significantly lower than before treatment（P＜0.05）, and the reduction in each index in the treatment group was more significant than that in the control group（P＜0.05）. After treatment, the serum ET-1, hs-CRP and LDL-C levels in two groups were significantly lower than before treatment（P＜0.05）, and the decrease in each index in the treatment group was more significant than that in the control group（P＜0.05）. Conclusion Compound Xueshuantong Capsule combined with diltiazem has significant curative effects on microvascular angina pectoris with Qiyin deficiency type, which can not only significantly improve the patient’s angina symptoms, disease severity and hemorheological indicators, but also improve the patient’s heart function status.

R972